Biotech Proxy Statements: Read Them Like an Activist

The problem: You read the 10-K, the 10-Q, and every press release. Then a proxy statement shows up in your EDGAR feed and you delete it. That is the exact document an activist reads first, because it is where the board’s real story lives. The CEO’s pay against the cash runway, the golden parachutes, the poison pill, and the related-party deals that decide whether a buyout is even possible all hide in the DEF 14A.

The solution: Read the proxy the way an activist reads it. Pull the definitive proxy, read the compensation table against the runway, check the change-in-control numbers, and scan the governance mechanics. Five sections, in order, and you will know more about the company’s real incentives than most of the sell-side.

Step 1: Pull the definitive proxy, not the preliminary

Schedule 14A is the SEC filing that discloses what shareholders are being asked to vote on and who is running the company. A PRE 14A is the preliminary draft, filed before the proxy is final. A DEF 14A is the definitive version, the one with final pay numbers, director nominees, and proposal text. Read the DEF 14A.

Find it on SEC EDGAR: search the ticker, filter form type to “DEF 14A”, open the latest. It drops ahead of the annual meeting, and also ahead of special meetings, which is where it matters most for biotech. An M&A vote, a proxy contest, or a reverse merger all trigger their own DEF 14A. The reverse-merger playbook is full of deals where the proxy was the only place the real terms appeared.

Step 2: Read the Summary Compensation Table against the runway

The Summary Compensation Table lists what the CEO and the top four named executive officers actually got paid: salary, bonus, stock awards, option awards, and the “all other compensation” catch-all. The number to benchmark is total comp against the cash runway.

The red flag is pay disconnected from survival. A pre-revenue biotech CEO earning $8 million a year while the company has eight months of cash is a board that is not aligned with shareholders. Run the same math from the dilution survival guide: cash divided by quarterly burn gives you months of runway. Then ask whether the CEO’s pay looks like a steward or an owner. The management framework walks the same logic one level deeper.

Step 3: Read the change-in-control and golden parachute numbers

The proxy discloses what each executive gets if the company is sold. These are the golden parachute payments, named after the Internal Revenue Code section 280G that taxes “excess” payouts at 20% once they cross three times the executive’s base pay. Most boards keep parachutes just under that 3x line to avoid the tax, which is why you will see the phrase “not to exceed 2.99x” in the fine print.

Why it matters: the parachute tells you whether the board is sale-friendly or entrenched. A modest parachute aligned with shareholders means a sale is not resisted. A CEO holding a large change-in-control package plus a poison pill is a board that will fight a bid, which matters if you are sizing a takeout bet. Run the sale-friendliness check against the 8-point M&A screen.

Step 4: Scan the governance red flags

This is the checklist activists use before they file a 13D. Four items:

• Staggered (classified) board: only a fraction of directors stand for election each year, so a hostile bidder cannot flip the whole board in one vote.
• Supermajority voting: mergers or bylaw changes need 66% or 75% approval instead of a simple majority.
• Poison pill (shareholder rights plan): triggers massive dilution if any holder crosses a threshold, usually 10 to 15%, blocking hostile accumulation.
• Dual-class shares: insiders hold super-voting stock, so public shareholders can vote but never actually win.

None of these is automatically bad, but stack two or three and you have a board that cannot be removed without a fight. That is the setup Kaos Capital is testing at Capricor, and the full mechanics are in the CAPR board fight piece. Carl Icahn built his biotech record on the same checklist at Genzyme and Amylin: find the entrenched board, force the governance fight, force the sale.

Step 5: Read “Certain Relationships and Related Transactions”

This section, named after Item 404 of Regulation S-K, discloses deals between the company and its officers, directors, or their affiliates. In biotech this is where conflicts hide. A company licensing its lead asset from a CEO-controlled entity is a conflict you want to see before you own the stock, not after.

It is also where deal contingencies get buried. When a buyer writes a contingent value right into a deal, the milestone definitions and the board’s rationale land in this section of the merger proxy. The CVR guide shows why: Gilead’s $5 per-share CVR for Arcellx pays only if anito-cel hits $6 billion in cumulative sales, and the exact threshold lives in the proxy, not the headline. Same lesson on the BioMarin and Ascendis patent settlement: the 20% Yuviwel royalty that looked like a “win-win” is really BioMarin monetizing the loss of its flagship, and the fine print that reveals it is in the settlement breakdown.

Step 6: Know how to vote and what it signals

Two votes matter. Say-on-pay is the non-binding shareholder vote on executive compensation, required since 2010 under Section 14A of the Exchange Act. It is advisory, but a failed vote is a loud signal that shareholders reject the pay package. Withholding your vote from a director nominee in an uncontested election is the standard protest: it does not remove the director, but a high withhold count embarrasses a board and telegraphs to activists that shareholder support is soft.

A DEF 14A is also how a proxy contest is actually fought. A 13D discloses a stake and intent; the DEF 14A is where the activist and the board each file competing proxy cards to win the vote. The activism piece explains the difference and why the filing, not the letter, is the catalyst.

Common mistakes

• Deleting the proxy because “the 10-K covers it.” The 10-K does not disclose the parachutes, the pill, or the related-party deals. The proxy does.
• Reading the compensation table without the runway next to it. $8 million means nothing until you know there are eight months of cash.
• Skipping the “certain relationships” section. It is where the conflicts and the deal contingencies actually live.
• Assuming a proxy contest and a 13D are the same thing. The 13D discloses; the DEF 14A is where the vote is won.

Final checklist

• Pull the DEF 14A on EDGAR, not the PRE 14A
• Compare CEO total comp to months of cash runway
• Read the change-in-control numbers: sale-friendly or entrenched?
• Count the governance flags: staggered board, supermajority, poison pill, dual-class
• Read “Certain Relationships and Related Transactions” line by line
• Note the say-on-pay result and any withheld director votes

The proxy is the one filing where the company has to tell you what its insiders are paid, who they are related to, and how hard they will fight to keep control. An activist reads it before anything else. So should you.